GERMANTOWN, Md., April 11, 2019 (GLOBE NEWSWIRE) -- Orgenesis Inc. (ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced that it has entered into a Collaboration and Licensing Agreement with ExcellaBio Ltd. for certain technologies developed by Sabina Glozman, Ph.D., including an exosome-like membrane nanostructure (Bioxome™) and related processes for the production of exosomes/extracellular vesicles (EVs). Under the Agreement, Orgenesis will have the exclusive, worldwide rights to certain commercial applications of the technology arising from the collaboration.
Vered Caplan, CEO of Orgenesis, said, “We are excited to collaborate with ExcellaBio and its founder, Dr. Glozman, on this breakthrough platform for the scalable production of exosomes/EVs. Exosomes have shown significant promise as a novel alternative to whole cell therapies with potentially superior safety, efficacy and storage/manufacturing properties.”
Sabina Glozman, Director of ExcellaBio Ltd., commented, “I am honored to partner with Orgenesis, a leader and pioneer in the field of cell therapy. By combining our unique exosome/EV technology with Orgenesis’ expertise within the cell therapy arena, this Collaboration has the potential to enhance many lives. We believe our Bioxome™ technology has very broad potential across a number of indications ranging from liver fibrosis to aesthetic indications, CNS disorders, as well as many other serious medical conditions.”
Orgenesis is a biotechnology company specializing in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. The Company operates through two platforms: (i) a point-of-care (“POCare”) cell therapy platform (“PT”) and (ii) a Contract Development and Manufacturing Organization (“CDMO”) platform conducted through its subsidiary, Masthercell Global. Through its PT business, the Company’s aim is to further the development of Advanced Therapy Medicinal Products (“ATMPs”) through collaborations and in-licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes to bring such ATMPs to patients. The Company out-licenses these ATMPs through regional partners to whom it also provides regulatory, pre-clinical and training services to support their activity in order to reach patients in a point-of-care hospital setting. Through the Company’s CDMO platform, it is focused on providing contract manufacturing and development services for biopharmaceutical companies. The CDMO platform operates through Masthercell Global, which currently consists of MaSTherCell in Belgium, Atvio in Israel and subsidiaries in South Korea and in the United States, each having unique know-how and expertise for manufacturing in a multitude of cell types. Additional information is available at: www.orgenesis.com.
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not a guarantee of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, the success of our reorganized CDMO operations, the success of our partnership with Great Point Partners, our ability to achieve and maintain overall profitability, the sufficiency of working capital to realize our business plans, the development of our transdifferentiation technology as therapeutic treatment for diabetes which could, if successful, be a cure for Type 1 Diabetes; our technology not functioning as expected; our ability to retain key employees; our ability to satisfy the rigorous regulatory requirements for new procedures; our competitors developing better or cheaper alternatives to our products and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended November 30, 2018, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.
Contact for Orgenesis:
Crescendo Communications, LLC